Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Selective cannabinoid-1 receptor blockade benefits fatty acid and triglyceride metabolism significantly in weight-stable nonhuman primates.

Vaidyanathan V, Bastarrachea RA, Higgins PB, Voruganti VS, Kamath S, DiPatrizio NV, Piomelli D, Comuzzie AG, Parks EJ.

Am J Physiol Endocrinol Metab. 2012 Sep 1;303(5):E624-34. doi: 10.1152/ajpendo.00072.2012. Epub 2012 Jul 3.

PMID:
22761159
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs.

Kim SP, Woolcott OO, Hsu IR, Stefanoski D, Harrison LN, Zheng D, Lottati M, Kolka C, Catalano KJ, Chiu JD, Kabir M, Ionut V, Bergman RN, Richey JM.

Am J Physiol Endocrinol Metab. 2012 May 1;302(10):E1261-8. doi: 10.1152/ajpendo.00496.2011. Epub 2012 Feb 28.

PMID:
22374758
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Fatty acid flux and oxidation are increased by rimonabant in obese women.

Backhouse K, Sarac I, Shojaee-Moradie F, Stolinski M, Robertson MD, Frost GS, Bell JD, Thomas EL, Wright J, Russell-Jones D, Umpleby AM.

Metabolism. 2012 Sep;61(9):1220-3. doi: 10.1016/j.metabol.2012.02.012. Epub 2012 Mar 24. Erratum in: Metabolism. 2014 Apr;63(4):e7.

PMID:
22445512
[PubMed - indexed for MEDLINE]
4.

Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet.

Flamment M, Gueguen N, Wetterwald C, Simard G, Malthièry Y, Ducluzeau PH.

Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1162-70. doi: 10.1152/ajpendo.00169.2009. Epub 2009 Sep 1.

PMID:
19724020
[PubMed - indexed for MEDLINE]
Free Article
5.

Does rimonabant independently affect free fatty acid and glucose metabolism?

Triay J, Mundi M, Klein S, Toledo FG, Smith SR, Abu-Lebdeh H, Jensen M.

J Clin Endocrinol Metab. 2012 Mar;97(3):819-27. doi: 10.1210/jc.2011-2486. Epub 2011 Dec 14.

PMID:
22170727
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats.

Chen W, Chen Z, Xue N, Zheng Z, Li S, Wang L.

Naunyn Schmiedebergs Arch Pharmacol. 2013 Aug;386(8):721-32. doi: 10.1007/s00210-013-0875-y. Epub 2013 Apr 26.

PMID:
23620336
[PubMed - indexed for MEDLINE]
7.

Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.

Tam J, Godlewski G, Earley BJ, Zhou L, Jourdan T, Szanda G, Cinar R, Kunos G.

Am J Physiol Endocrinol Metab. 2014 Feb 15;306(4):E457-68. doi: 10.1152/ajpendo.00489.2013. Epub 2013 Dec 31.

PMID:
24381003
[PubMed - indexed for MEDLINE]
8.

Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats.

Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschöp J, Caldwell C, Woods SC, Wittmann G, Watanabe M, Liposits Z, Fekete C, Reizes O, Rohner-Jeanrenaud F, Tschöp MH.

Diabetes. 2008 Nov;57(11):2977-91. doi: 10.2337/db08-0161. Epub 2008 Aug 20.

PMID:
18716045
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism.

Cota D, Sandoval DA, Olivieri M, Prodi E, D'Alessio DA, Woods SC, Seeley RJ, Obici S.

Obesity (Silver Spring). 2009 Aug;17(8):1641-5. doi: 10.1038/oby.2009.84. Epub 2009 Mar 26.

PMID:
19325539
[PubMed - indexed for MEDLINE]
10.

Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice.

Bell-Anderson KS, Aouad L, Williams H, Sanz FR, Phuyal J, Larter CZ, Farrell GC, Caterson ID.

Int J Obes (Lond). 2011 Dec;35(12):1539-48. doi: 10.1038/ijo.2011.55. Epub 2011 Mar 8.

PMID:
21386801
[PubMed - indexed for MEDLINE]
11.

Effects on food intake and blood lipids of cannabinoid receptor 1 antagonist treatment in lean rats.

Bennetzen MF, Nielsen MP, Richelsen B, Pedersen SB.

Obesity (Silver Spring). 2008 Nov;16(11):2451-5. doi: 10.1038/oby.2008.390. Epub 2008 Aug 14.

PMID:
18719671
[PubMed - indexed for MEDLINE]
12.

CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice.

Jourdan T, Djaouti L, Demizieux L, Gresti J, Vergès B, Degrace P.

Diabetes. 2010 Apr;59(4):926-34. doi: 10.2337/db09-1482. Epub 2010 Jan 28.

PMID:
20110567
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs.

Richey JM, Woolcott OO, Stefanovski D, Harrison LN, Zheng D, Lottati M, Hsu IR, Kim SP, Kabir M, Catalano KJ, Chiu JD, Ionut V, Kolka C, Mooradian V, Bergman RN.

Am J Physiol Endocrinol Metab. 2009 Jun;296(6):E1311-8. doi: 10.1152/ajpendo.90972.2008. Epub 2009 Apr 14.

PMID:
19366874
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Chronic ethanol and triglyceride turnover in white adipose tissue in rats: inhibition of the anti-lipolytic action of insulin after chronic ethanol contributes to increased triglyceride degradation.

Kang L, Chen X, Sebastian BM, Pratt BT, Bederman IR, Alexander JC, Previs SF, Nagy LE.

J Biol Chem. 2007 Sep 28;282(39):28465-73. Epub 2007 Aug 7.

PMID:
17686776
[PubMed - indexed for MEDLINE]
Free Article
15.

Metabolic responses to long-term pharmacological inhibition of CB1-receptor activity in mice in relation to dietary fat composition.

Koolman AH, Bloks VW, Oosterveer MH, Jonas I, Kuipers F, Sauer PJ, van Dijk G.

Int J Obes (Lond). 2010 Feb;34(2):374-84. doi: 10.1038/ijo.2009.219. Epub 2009 Oct 20.

PMID:
19844210
[PubMed - indexed for MEDLINE]
16.

Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis.

O'Hare JD, Zielinski E, Cheng B, Scherer T, Buettner C.

Diabetes. 2011 Apr;60(4):1055-62. doi: 10.2337/db10-0962.

PMID:
21447652
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.

Després JP, Ross R, Boka G, Alméras N, Lemieux I; ADAGIO-Lipids Investigators.

Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):416-23. doi: 10.1161/ATVBAHA.108.176362. Epub 2008 Dec 26.

PMID:
19112166
[PubMed - indexed for MEDLINE]
Free Article
18.

Parallel activation of de novo lipogenesis and stearoyl-CoA desaturase activity after 3 d of high-carbohydrate feeding.

Chong MF, Hodson L, Bickerton AS, Roberts R, Neville M, Karpe F, Frayn KN, Fielding BA.

Am J Clin Nutr. 2008 Apr;87(4):817-23.

PMID:
18400702
[PubMed - indexed for MEDLINE]
Free Article
19.

Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice.

Bajzer M, Olivieri M, Haas MK, Pfluger PT, Magrisso IJ, Foster MT, Tschöp MH, Krawczewski-Carhuatanta KA, Cota D, Obici S.

Diabetologia. 2011 Dec;54(12):3121-31. doi: 10.1007/s00125-011-2302-6. Epub 2011 Oct 11.

PMID:
21987346
[PubMed - indexed for MEDLINE]
20.

The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.

Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Péleraux A, Pénarier G, Soubrié P, Le Fur G, Galiègue S, Casellas P.

FASEB J. 2005 Sep;19(11):1567-9. Epub 2005 Jul 11.

PMID:
16009704
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk